MAP2K7 and melanoma: In addition to the established interventions using BRAF and MEK inhibitors, HSP90 inhibitors for patients with the BRAFV600-mutant melanoma are under investigation due to their manageable side-effect profiles when combined with BRAFi.348 HSP90 inhibitors, such as AT13387 or XL888, offer a promising strategy to combat drug resistance resulting from BRAF and MEK inhibition in melanomas.348 Clinical trials investigating the combination of BRAF/MEKi with XL888 or AT13387 are currently underway (NCT02721459, NCT02097225).